2024
2bind GmbH, a leading contract research organization (CRO) specializing in biophysical analysis for drug discovery and antibody development, today announced a transition in its executive leadership. Dr. Thomas Schubert, Co-CEO,
2bind GmbH Opens New Headquarters to as a Result of Quality Work and Continued Growth
2023
2bind GmbH Elevates Dr. Cosimo Kropp to Chief Business Officer
2bind GmbH Launches Antibody Unit with Appointment of Dr. Vera Molkenthin as Director
2021
2bind GmbH Strengthens Business Development with Appointment of Dr. Cosimo Kropp
A collaborative research project based in Regensburg is leveraging cutting-edge technology and expertise to develop a novel drug against COVID-19. The project unites 2bind GmbH, a leading biophysical analysis company
The federally funded interdisciplinary research project “HIVacToGC” was launched to investigate new approaches to the prevention and treatment of HIV infections.
2019
2bind wins first place in the EU's Eureka Eurostars competition, together with partners from the Netherlands and Great Britain.
2bind GmbH Appoints Dr. Maximilian Plach as COO to Oversee Rapid Growth
2018
2bind GmbH and Assay.Works Join Forces to Expand Drug Discovery Services
2017
2bind GmbH Appoints Dr. Maximilian Plach as CSO to Drive Biophysics in Drug Discovery
2bind GmbH Appoints Dr. Thomas Schubert as CEO to Lead Strategic Shift Towards Drug Discovery Research Services .
2bind GmbH Relaunches with Renewed Focus on Empowering Drug Discovery through Biophysical Research Services.